How is Nilotinib reimbursed by medical insurance?

Nilotinib (Nilotinib), which is marketed in China, has entered the Class B medical insurance category through the relevant policies of the National Medical Insurance Administration. The general name is nilotinib, but reimbursement is limited to patients who meet the indications, including newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) chronic phase adult patients and pediatric patients over 2 years old; and For adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in the chronic or accelerated phase who are resistant or intolerant to previous treatments (including imatinib) and children over 2 years old in the chronic phase, the price of each box of 150mg*120 capsules may be around RMB 9,000. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. Patients can consult the local medical insurance bureau or hospital.